Nature Reviews Rheumatology - Table of Contents alert Volume 11 Issue 6

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
June 2015 Volume 11 Number 6
Impact Factor 10.252 *	In this issue Research Highlights News and Views Reviews Perspectives Also this month  Featured article: Cellular imaging in rheumatic diseases Robert A. Benson, Iain B. McInnes, James M. Brewer & Paul Garside
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Nature Communications is now fully open access All new submissions if accepted, will be published open access and an article processing charge will apply. For more information visit the website. Visit our open access funding page or contact openaccess@nature.com to learn more on APC funding.
RESEARCH HIGHLIGHTS Top Experimental arthritis: Fullerene nanoparticles ameliorate disease in arthritis mouse model Published online: 05 May 2015 p319 | doi:10.1038/nrrheum.2015.62 PDF Inflammation: Soluble MRP8/14 recruits neutrophils via TLR4 Published online: 05 May 2015 p320 | doi:10.1038/nrrheum.2015.63 PDF Pharmacotherapy: Going upstream: peptidomimetics block shared-epitope signalling Published online: 05 May 2015 p320 | doi:10.1038/nrrheum.2015.64 PDF
NEWS AND VIEWS		Top
Rheumatoid arthritis: IL-6 inhibition in RA—déjà vu all over again? Eric M. Ruderman Published online: 28 April 2015 p321 | doi:10.1038/nrrheum.2015.58 In a phase II-III trial, a novel antibody targeting IL-6 receptor α (IL-6Rα), sarilumab, conferred clinical, functional and structural benefits in rheumatoid arthritis. These results, though, seem quite similar to those for tocilizumab, the existing anti-IL-6Rα antibody, as well as for other agents currently in development that target this same pathway. Full Text | PDF
Therapy: Facing up to biosimilar agents—the ACR position Morton Scheinberg Published online: 28 April 2015 p322 | doi:10.1038/nrrheum.2015.57 As patents expire for biologic reference products (innovators), biosimilar agents are joining the treatment landscape in rheumatology. Release of an ACR position statement on biosimilars prompts US rheumatologists to focus on issues relating to the clinical use of these agents and can also be helpful for rheumatologists in other regions where biosimilar agent regulatory processes are not yet fully implemented. Full Text | PDF
Clinical trials: A transparent future for clinical trial reporting Fotini B. Karassa & John P. A. Ioannidis Published online: 05 May 2015 p324 | doi:10.1038/nrrheum.2015.65 Compliance with reporting clinical trial results varies across research fields and types of sponsors. In rheumatology, most industry-funded trials of biologic agents are currently reported promptly. Optimizing clinical research will nevertheless require steps beyond deposition of summary results, including making raw data and protocols available, and assuring independence of the research agenda. Full Text | PDF | Supplementary information
Connective tissue diseases: The burden of serious infections in SLE Jessica Widdifield & Sasha Bernatsky Published online: 21 April 2015 p326 | doi:10.1038/nrrheum.2015.55 Is the risk of hospitalization and death due to serious infections on the rise in patients with systemic lupus erythematosus (SLE)? A population-based study provides insights into these trends and highlights the need for safe, effective treatment strategies in SLE. Full Text | PDF
REVIEWS		Top
Trojan horses and guided missiles: targeted therapies in the war on arthritis Mathieu Ferrari, Shimobi C. Onuoha & Costantino Pitzalis Published online: 03 March 2015 p328 | doi:10.1038/nrrheum.2015.17 Despite the successes of biologic therapies in rheumatoid arthritis (RA), not all patients respond to available drugs, and systemic toxicity of some drugs often lead to therapy discontinuation. New developments in polymer–drug conjugates and nanoparticle technology can improve drug efficacy in patients with RA by targeting therapeutic agents to inflamed tissues and extending the half-life of drugs. In this Review, Ferrari and colleagues describe new techniques being explored to improve accumulation of therapeutic agents in the inflamed synovium—a new strategy to boost drug efficacy at disease sites without affecting healthy tissues. Abstract | Full Text | PDF
Uveitis associated with juvenile idiopathic arthritis Ethan S. Sen, Andrew D. Dick & Athimalaipet V. Ramanan Published online: 31 March 2015 p338 | doi:10.1038/nrrheum.2015.20 The most common form of eye inflammation associated with juvenile idiopathic arthritis (JIA) is chronic anterior uveitis, which, if inadequately treated, can lead to ocular complications, including blindness. Sen and colleagues discuss the epidemiology, immunopathogenesis and management of JIA-associated uveitis, and describe the potential for biomarkers to improve its treatment. Abstract | Full Text | PDF
Clocking in: chronobiology in rheumatoid arthritis Frank Buttgereit, Josef S. Smolen, Andrew N. Coogan & Christian Cajochen Published online: 24 March 2015 p349 | doi:10.1038/nrrheum.2015.31 Circadian rhythms are well established as having an important role in human biology. In this Review, circadian biology is presented in reference to the regulation of rheumatoid arthritis and the potential for chronotherapeutic intervention. Abstract | Full Text | PDF
Cellular imaging in rheumatic diseases Robert A. Benson, Iain B. McInnes, James M. Brewer & Paul Garside Published online: 24 March 2015 p357 | doi:10.1038/nrrheum.2015.34 Several molecular pathways and cellular effector functions have been described for the pathology of rheumatoid arthritis, but fundamental questions remain about the basic organization of disease-driving immune responses. In this Review, Benson and colleagues describe how intact tissue imaging in vivo has facilitated studies of the dynamic nature of cellular immune responses, and how these findings can be translated to new therapeutics. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION A pathogenetic role for IL-21 in primary Sjögren syndrome Seung-Ki Kwok, Jennifer Lee, Di Yu, Kwi Young Kang, Mi-La Cho, Hae-Rim Kim, Ji Hyeon Ju, Sang-Heon Lee, Sung-Hwan Park & Ho-Youn Kim Published online: 13 January 2015 p368 | doi:10.1038/nrrheum.2014.225 Kim et al. hypothesize that IL-21 is crucial to the pathogenesis of primary Sjögren syndrome (pSS), focusing on evidence of an interplay between the innate and adaptive immune responses mediated by the effects of IL-21 on immune cells. This new perspective might ultimately offer insight into novel approaches to the treatment of pSS. Abstract | Full Text | PDF
OPINION Article series: APLAR Perspectives Genetics of rheumatoid arthritis in Asia—present and future Kazuhiko Yamamoto, Yukinori Okada, Akari Suzuki & Yuta Kochi Published online: 10 February 2015 p375 | doi:10.1038/nrrheum.2015.7 Genetic factors play an important part in the disease heterogeneity observed in patients with rheumatoid arthritis (RA). Genome-wide association studies (GWAS) have linked common single-nucleotide polymorphisms with the risk of developing RA, but have also highlighted the genetic heterogeneity between Asian and European patients with this disease. In this Perspectives article, the authors discuss recent advances from GWAS in Asian patients with RA, and suggest that better knowledge of the interface between genetic and environmental factors could help our understanding of the disease. Abstract | Full Text | PDF | Supplementary information
Advertisement
Presented by Adaptive Biotechnologies, Nature Immunology, Nature Medicine, Nature Biotechnology, and Nature Genetics IMMUNE PROFILING IN HEALTH AND DISEASE September 9-11, 2015 | Seattle, WA, USA REGISTER NOW!
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2013. Nature Reviews Rheumatology was previously published as Nature Clinical Practice Rheumatology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.